The company has not filed an annual or quarterly report since its Q3 FY2023 10-Q, filed Feb 9, 2023. Its latest SEC filing is a 15-12G from Jun 30, 2023.
10-Q for Q3 FY2023, filed Feb 9, 2023
The sections below describe the company as of the FY2022 annual report.
Sells blood-grouping reagents and quality-control products to hospitals, donor testing laboratories, and diagnostics companies, while developing a microarray platform for blood grouping and disease screening.
10-K for FY2022, filed Jun 28, 2022We have a proven track record and significant expertise in product development, manufacturing and quality assurance, tailored to the highly…View ↗
We have over 30 years of experience developing, manufacturing and commercializing conventional reagent products used for blood grouping…View ↗
Our initial aim is to provide donor testing laboratories with a single instrument platform to be utilized for blood grouping and, if…View ↗
Customers pay for conventional reagent products when goods ship; OEM product-development fees are earned when agreed milestones are achieved.
10-K for FY2022, filed Jun 28, 2022We generate product sales revenue from the sale of conventional reagent products directly to hospitals, donor collection agencies and…View ↗
Product revenue is recognized at a point in time upon transfer of control of a product to a customer, which is generally at the time of…View ↗
Revenue is also earned from the provision of development services to a small number of original equipment manufacturer ("OEM") customers.…View ↗
10-K for FY2022, filed Jun 28, 2022
FY2022 revenue by product or service ↗$38.5M
10-K for FY2022, filed Jun 28, 2022
$38.5M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product Sales
Sold outright
10-K for FY2022, filed Jun 28, 2022 |
99%
FY2019: 98%
|
Product Sales, FY2022
$38.3M Sources
|
Sold outright |
|
Other Revenues
Sold outright
|
0.6%
FY2019: 1.6%
|
Other Revenues, FY2022
$231K Sources
|
Sold outright |
Hospitals, donor collection agencies and independent testing laboratories buy products directly in the United States; elsewhere, sales go through distributors and OEMs. OEMs buy reagent products for use with their instruments.
10-K for FY2022, filed Jun 28, 2022In the United States, we currently offer directly to our customers a portfolio of 81 conventional reagent products focused on blood…View ↗
We sell the majority of our conventional reagent products to our OEM customers for use with their blood grouping instruments as specific…View ↗
We market our conventional reagent products directly in the United States. Outside of this territory, we sell our products to a range of…View ↗
No. It lost $125.1M in FY2022.
10-K for FY2022, filed Jun 28, 2022
−$103.8MView ↗
10-K for FY2022, filed Jun 28, 2022
−$125.1MView ↗
10-K for FY2022, filed Jun 28, 2022
−$121.9MView ↗
10-Q for Q3 FY2023, filed Feb 9, 2023
−$13.3MView ↗
10-Q for Q3 FY2023, filed Feb 9, 2023
Open tableView ↗
8-K, filed Jun 14, 2023
On the Closing Date, each shareholder of the Company whose name appeared on the register of members of the Company (other than MergerCo…View ↗
8-K, filed Feb 22, 2023
2. commenced, on January 10, 2023 (the “Petition Date”), this Chapter 11 Case by filing a voluntary petition for relief under chapter 11 of…View ↗
8-K, filed Dec 19, 2022
On December 12, 2022, the Company notified the Nasdaq Stock Market LLC of its intention to voluntarily withdraw its ordinary shares from…View ↗
Grew. Revenue grew 56% in 4 years, from $24.7M in FY2018 to $38.5M in FY2022, about 12% a year.
Clinical testing
The earlier report described broad immunoassay and molecular testing opportunities beyond transfusion diagnostics; the later report identifies allergy and autoimmune microarrays as a specific clinical-diagnostics focus.
10-K for FY2019, filed May 29, 2019 10-K for FY2022, filed Jun 28, 2022
COVID testing
The earlier product plan covered blood grouping and donor disease screening; the later portfolio also includes a COVID testing microarray.
10-K for FY2019, filed May 29, 2019 10-K for FY2022, filed Jun 28, 2022
Competes with Ortho, Beckman Coulter, Immucor, Grifols, Abbott, Roche, Bio-Rad, Merck/Millipore, and Diagast
10-K for FY2022, filed Jun 28, 2022For Immunohematology, the principal market participants in the United States are Ortho, Beckman Coulter, Immucor and Grifols. The principal…View ↗
Loading...
